this has to be a fantastic buy at £1.17.wish i had some ammo but i am already all in,gl,jim
Hi FM : Yes unclear what other transformational event could occur before mid-2015 to kick start higher market cap value ? ( AIM market bit ropey these days ) CEO : "The initiation of this trial means our DMD and CDI programmes have the potential to achieve important clinical milestones in the near-term with both expected to report top-line data in mid-2015." Hopefully adequate cash reserves to service operations next 6 months , obviously better for Summit to have some positive clinical data before embarking on the fund raising trail –few scenarios could come into play ,depending on outcomes ! DMD : Other companies involved with DMD drug development making progress, but also face challenges & setbacks ! In Germany PTC Translarna approved - yet NHS still making up their mind! “First drug for the underlying cause of nonsense mutation Duchenne muscular dystrophy –“ http://finance.yahoo.com/news/ptc-therapeutics-announces-launch-translarna-130000092.html Yet very same drug: “NHS bosses have halted assessment of a pioneering drug from Newcastle used to tackle a rare muscle-wasting condition . http://www.chroniclelive.co.uk/news/health/nhs-bosses-halted-assessment-pioneering-8224028/RK=0/RS=mGqA_jLPIcO2unQPN5jJRHl51RA- Sarepta : The submission of an NDA for eteplirsen will be delayed by about six months from its original 2014 goal. Sarepta understands the desire of the FDA to have as much additional information as possible and wants to honor the agency's requests, with the goal of creating as strong an application for eteplirsen as possible. http://quest.mda.org/news/sarepta-reaffirms-commitment-eteplirsen-other-dmd-drugs " Glaxo forges $680M RNA pact with Prosensa few years back - withdrew recently & handed drug back - maybe shrewd move by Prosensa as they then got bought by Biomarin - ( drug data results mixed to say the least) Perhaps Summit steady as you go approach & adhering strictly to regulatory approval testing criteria process will eventually provide positive data that supports the claim “100% of patient population & potential to be monotherapy or complementary to other therapies “ Very frustrating though for those DMD patients desperate for a treatment cure & not great for investors - did think 2013 then 2014 ,perhaps 2015 ,now more likely 2016/2017 for DMD SMTC1100 treatment cure ! Fair to say at the moment , Summit still under the radar compared to others , reflected in current market cap values ! Good luck everyone !
That a great post Gerry. Clarifies why we and the company will not know the official results until the final report is produced. We at least know the supporting data from previous studies demonstrates this should be 'a walk in the park' and 'a free ride for shareholders'. I expect the SP will pick early next year in traditional buying season as investors set their positions for the year. There are not many shares available so I expect even moderate demand could shift the share price significantly. Or I may be wrong and the market might not react until they see P2 results. Either way it's only going one way from here next year. GLA
FYI: Good explanation! http://www.billingsclinic.com/research/clinical-trials/details/?id=29 “C Difficile A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 (200 mg BID) for 10 days Compared with Vancomycin (125 mg QID) for 10 days for the Treatment of Clostridium difficile-Associated Diarrhoea (CDAD) Objective This study involves the use of an investigational study medication known as SMT19969 which will be compared to vancomycin, an antibiotic already used in the treatment of CDAD. SMT19969 is an investigational medication. Investigational means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). Vancomycin is approved by the U.S. FDA for the treatment of CDAD. The purpose of this study is to test the safety and effectiveness of SMT19969 compared to vancomycin. Qualifications: •Age 18 to 90 •Positive C Difficile Lab Value within the last 24 hours More Information: If you qualify for the study you will be placed in one of the following treatment groups. You will be randomly assigned by chance (like the flip of a coin) to receive either SMT19969 and placebo or vancomycin. The placebo looks like SMT19969 but does not have any active substance. You have a 50% chance of receiving SMT19969 or vancomycin. The term "study drug" refers to both SMT19969 and placebo and vancomycin. The study is blinded. This means that no one will know which study drug you are taking. .All study drug will look the same so you will not be able to tell which study drug you are taking. Neither you, the study staff, the study doctor nor anyone at the company sponsoring the study will know if you are on SMT19969 or vancomycin. But, if there is an emergency, the study doctor and the study staff can get this information right away. If you agree to participate in this study, you will have at least 7 visits and last approximately 40 days. COSTS OF PARTICIPATION: You (and/or your insurance company) will not be expected to pay for any of the procedures that are part of this research study. Also, you (and/or your insurance company) will not be expected to pay for the study drug(s) or tests that are part of this research study. You will be paid $40.00 for each completed study visit. IRB Protocol Number SMT19969/C002 Principal Investigator(s) Camilla Saberhagen, MD Sponsor(s) Summit Corporation Contact Recruitment Hotline at 406-657-4111 or email@example.com” Medical jargon explained ! http://en.wikipedia.org/wiki/Randomized_controlled_trial http://labtestsonline.org.uk/understanding/analytes/cdiff/tab/test/ Good luck everyone!
Superbugs to kill 'more than cancer
Worth a read http://www.bbc.co.uk/news/health-30416844
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.